Article Menu

Export Article

More by Authors Links

Article Data

  • Views 1094
  • Dowloads 138

Original Research

Open Access

Clinical features of familial ovarian cancer lacking mutations in BRCAI or BRCA2

  • J. Menkiszak1,*,
  • J. Gronwald2
  • B. Górski2
  • T. Byrski2
  • T. Huzarski2
  • A. Jakubowska2
  • M. Foszczyriska-Kloda3
  • M. Brzosko4
  • J. Fliciriski4
  • I. Rzepka-G6rska1
  • S.A. Narod5
  • J. Lubiriski2

1Clinic of Swgical Gynecology and Gynecological Oncology of Adults and Adolescents, Pomeranian Medical University， Szczecin

2Hereditary Cancer Center, Department of Genetics and Pathology, Pomeranian Medical University, Szczecin

3Department of Chemotherapy, Regional Oncology Hospital, Szczecin

4Clinics of Rheumatology, Pomeranian Medical University, Szczecin, Poland

5Centre for Research in Womens Health, Sunnybrook and Womens' College Health Sciences Center, University of Toronto, Toronto, Ontario, Canada

DOI: 10.12892/ejgo20040199 Vol.25,Issue 1,January 2004 pp.99-100

Published: 10 January 2004

*Corresponding Author(s): J. Menkiszak E-mail:

PDF (281.8 kB) View Full-text

Abstract

Purpose of investigation: The purpose of the present study was to identify the clinical and pathologic features of ovarian cancers in patients who have a family history of breast or ovarian cancer but who do not have a mutation in the BRCA1 or BRCA2 gene.

Methods: 303 patients with ovarian cancer were reviewed for clinical features and for cancer family histories. After the exclusion of 51 patients known to carry BRCA1 or BRCA2 mutations, 24 patients with familial cancer were compared with 228 patients with non-familial cancer.

Results: Patients with familial cancer were more likely to have grade 2 tumors, Stage II disease and to present between ages 51 and 60 than were non-familial controls. Ten of 24 patients in the familial group presented between ages 51 and 60 with a grade 2 tumor compared to 3.0 expected (p = 0.001).

Conclusions: Families of women who present with grade 2 ovarian cancer between the ages of 51 and 60 may have an unidentified ovarian cancer susceptibility gene.

Keywords

Hereditary ovarian cancer; Epidemiology; BRCAJ; Poland

Cite and Share

J. Menkiszak,J. Gronwald,B. Górski,T. Byrski,T. Huzarski,A. Jakubowska,M. Foszczyriska-Kloda,M. Brzosko,J. Fliciriski,I. Rzepka-G6rska,S.A. Narod,J. Lubiriski. Clinical features of familial ovarian cancer lacking mutations in BRCAI or BRCA2. European Journal of Gynaecological Oncology. 2004. 25(1);99-100.

URL:

https://www.ejgo.net/articles/10.12892/ejgo20040199

References

[1] Risch H.A., McLaughlin J.R., Cole D.E.C., Rosen B., Bradley L., Kwan E. et al.: "Prevalence and penetrance of germline BRCAl and BRCA2 mutations in a population series of 649 women with ovarian cancer". Am. J. Hum. Genet., 2001, 68, 700.

[2] Gorski B., Byrski T., Huzarski T., Jakubowska A., Menkiszak J., Gronwald J. etal.: "Founder mutations in the BRCA-1 in polish farnilies with breast-ovarian cancer". Am. J. Hum. Genet., 2000, 66, 1963.

[3] J. Menkiszak, J. Gronwald, B. Gorski, A. Jakubowska, T. Huzarski, T. Byrski et al.: "Hereditary ovarian cancer in Poland". Int. J. Cancer, 2003, 106 (6), 942.

[4] Lakhani S.R., Jacquemier J., Sloane J.P. et al.: "Multifactorial analyses of differences between sporadic breast cancers and cancers involving BRCAl and BRCA2 mutations". J. Natl. Cancer Inst., 1988, 90, 1138.

[5] The Breast Cancer Linkage Consortium: "Cancer risks in BRCA2 mutation carriers". J. Natl. Cancer Inst., 1999, 35, 1310.

[6] Moslehi R., Chu W., Karlan B., Fishman D., Risch H., Fields A. et al.: "BRCA I and BRCA2 mutation analysis of 208 Ashkenazi Jewish women with ovarian cancer". Am. J. Hum. Genet., 2000, 6, 1259.

[7] Boyd J., Sonoda Y., Federici M., Bogomolniy F., Rhei E., Maresco D.L. et al.: "Clinicopathologic features of BRCA-linked and sporadic ovarian cancer". J. Amer. Medic. Assoc., 2000, 283, 2260.

[8] Stratton J.P., Thompson D., Bobrow L., Dalal N., Gore M., Bishop D.T. et al.: "The genetic epidemiology of early-onset epithelial ovarian cancer: a population-based study". Am. J. Hum. Genet., 1999, 65, 1724.

Submission Turnaround Time

Top